This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Tecemotide
- DrugBank Accession Number
- DB12568
- Background
Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Tecemotide
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Tecemotide can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Tecemotide can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Tecemotide can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Tecemotide can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Tecemotide can be decreased when used in combination with Alemtuzumab. Altretamine The therapeutic efficacy of Tecemotide can be decreased when used in combination with Altretamine. Amsacrine The therapeutic efficacy of Tecemotide can be decreased when used in combination with Amsacrine. Anakinra The therapeutic efficacy of Tecemotide can be decreased when used in combination with Anakinra. Antilymphocyte immunoglobulin (horse) The therapeutic efficacy of Tecemotide can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Antithymocyte immunoglobulin (rabbit) The therapeutic efficacy of Tecemotide can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit). 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Q7Y026G2CX
- CAS number
- 221214-84-2
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911345
- Wikipedia
- Tecemotide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Non-Small Cell Lung Carcinoma (NSCLC) 1 3 Terminated Treatment Breast Cancer 1 3 Terminated Treatment Non-Small Cell Lung Carcinoma (NSCLC) 2 2 Completed Treatment Lung Cancers 1 2 Completed Treatment Multiple Myeloma (MM) 1 2 Completed Treatment Neoplasms, Lung / Non-Small Cell Lung Carcinoma (NSCLC) 2 2 Completed Treatment Prostate Cancer 1 2 Completed Treatment Rectal Carcinoma 1 1, 2 Completed Treatment Non-Small Cell Lung Carcinoma (NSCLC) 1 Not Available Terminated Treatment Multiple Myeloma (MM) / Non-Small Cell Lung Carcinoma (NSCLC) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at October 20, 2016 22:55 / Updated at February 21, 2021 18:53